Literature DB >> 10831359

Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography.

D Grab1, F Flock, I Stöhr, K Nüssle, A Rieber, S Fenchel, H J Brambs, S N Reske, R Kreienberg.   

Abstract

OBJECTIVE: The purpose of this study was to determine the diagnostic accuracy of sonography versus magnetic resonance imaging (MRI) and positron emission tomography (PET) in the characterization of adnexal masses.
METHODS: One hundred and one patients with asymptomatic adnexal masses, which were scheduled for laparoscopy, underwent preoperative transvaginal ultrasound, MRI, and 2-[(18)F]fluoro-2-deoxy-d-glucose PET. Two different sonomorphological scoring systems were used to distinguish malignant from benign lesions. In addition, transvaginal Doppler flow velocimetry was performed and the resistance index (RI) of ovarian blood vessels was calculated. RI values below 0.45 were considered to indicate malignancy. MRI was evaluated on the basis of signal intensity and morphologic features such as wall thickness, septations, fluid or solid components, and vascularity. PET imaging was used to determine 2-[(18)F]fluoro-2-deoxy-D-glucose uptake. Malignancy was suspected if radiotracer uptake equaled or exceeded that of the liver. Based on histologic findings, sensitivity, specificity, positive and negative predictive values, and accuracy were first calculated independently for each imaging technique. Finally, a second session resulted in a consensus diagnosis being made based on the findings of all three modalities.
RESULTS: Sonographic evaluation of adnexal masses resulted in correct classification of 11 of 12 ovarian malignancies (sensitivity 92%) but with a specificity of only 60%. With MRI and PET, specificities improved to 84 and 80% respectively, but sensitivities decreased. When all imaging modalities were combined, sensitivity and specificity were 92 and 85%, respectively, and accuracy was 86%.
CONCLUSION: Combination of ultrasound with MRI and PET may improve accuracy in differentiation of benign from malignant ovarian lesions. However, negative MRI or PET results do not rule out early-stage ovarian cancer or borderline malignancies. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831359     DOI: 10.1006/gyno.2000.5768

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  18 in total

Review 1.  An update on the role of PET/CT and PET/MRI in ovarian cancer.

Authors:  Benjapa Khiewvan; Drew A Torigian; Sahra Emamzadehfard; Koosha Paydary; Ali Salavati; Sina Houshmand; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-08       Impact factor: 9.236

2.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

3.  A new computer-aided diagnostic tool for non-invasive characterisation of malignant ovarian masses: results of a multicentre validation study.

Authors:  Olivier Lucidarme; Jean-Paul Akakpo; Seth Granberg; Mario Sideri; Hanoch Levavi; Achim Schneider; Philippe Autier; Dror Nir; Harry Bleiberg
Journal:  Eur Radiol       Date:  2010-03-20       Impact factor: 5.315

4.  Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

5.  Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.

Authors:  B Böhm; M Voth; J Geoghegan; H Hellfritzsch; A Petrovich; J Scheele; D Gottschild
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-06       Impact factor: 4.553

6.  The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors.

Authors:  Hyo Young Jeoung; Han Song Choi; Yo Sup Lim; Min Young Lee; Soo A Kim; Sei Jun Han; Tae Gyu Ahn; Sang Joon Choi
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

7.  2-deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines.

Authors:  A M Lutz; P Ray; J K Willmann; Charles Drescher; S S Gambhir
Journal:  Mol Imaging Biol       Date:  2007 Sep-Oct       Impact factor: 3.488

8.  Evaluation of primary adnexal masses by 3T MRI: categorization with conventional MR imaging and diffusion-weighted imaging.

Authors:  He Zhang; Guo-Fu Zhang; Zhi-Yan He; Zheng-Yu Li; Ming Zhu; Gui-Xiang Zhang
Journal:  J Ovarian Res       Date:  2012-11-14       Impact factor: 4.234

9.  The serum CA-125 concentration data assists in evaluating CT imaging information when used to differentiate borderline ovarian tumor from malignant epithelial ovarian tumors.

Authors:  Ji-Eun Shin; Hyuck Jae Choi; Mi-Hyun Kim; Kyoung-Sik Cho
Journal:  Korean J Radiol       Date:  2011-07-22       Impact factor: 3.500

Review 10.  PET/CT and cross sectional imaging of gynecologic malignancy.

Authors:  Revathy B Iyer; Aparna Balachandran; Catherine E Devine
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.